(NewsDirect)
Race Oncology CEO Damian Clark-Brucejoined Steve Darling from Proactive to share significant news aboutthe company's recent agreements and partnerships.
Firstly, Race Oncology has signed anagreement with Ardena Holding, a global contract development andmanufacturing organization. This collaboration will provide additionalGood Manufacturing Practice -standard manufacturing capability for itsflagship IV formulation of bisantrene, RC220. Ardena is a fullyintegrated CDMO known for its expertise in assisting biopharmacompanies throughout the drug development life cycle, including theproduction of sterile injectable products for clinical development.
Clark-Bruce further explained toProactive that this partnership with Ardena strengthens RaceOncology's existing manufacturing programs, as it establishes aprimary source for EU-compliant supplies of RC220. This isparticularly important for EU clinical studies, ensuring theavailability of high-quality, GMP-compliant formulations of RC220.
Additionally, Clark-Bruce shared news about an exclusivelicense agreement with City of Hope, a prominent US cancer researchand treatment organization. Through this agreement, Race Oncologygains access to City of Hope's intellectual property, whichhighlights bisantrene as a potent inhibitor of the human fat mass andobesity-associated protein. This discovery opens up new possibilitiesfor exploring the therapeutic potential of bisantrene beyond itsestablished use as an anti-cancer agent.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.